Activation of the PGE2–EP2 pathway as a potential drug target for treating eosinophilic rhinosinusitis
Current treatments of eosinophilic chronic rhinosinusitis (ECRS) involve corticosteroids with various adverse effects and costly therapies such as dupilumab, highlighting the need for improved treatments. However, because of the lack of a proper mouse …